The Law of Diminishing Returns in Clinical Medicine: How Much Risk Reduction is Enough?

References

1. ↵
   Economy Professor. Law of diminishing returns. The Professor Network, 2009. Available at www.economyprofessor.com/economictheories/law-of-diminishing-returns.php. Accessed 14 April 2009.
2. ↵
   Johnson HA. Diminishing returns on the road to diagnostic certainty. JAMA 1991; 265: 2229–31.

   OpenUrlCrossRefPubMedWeb of Science
3. ↵
   Sonnenberg A. Diminishing returns on sequential interventions of gastroenterology. Eur J Gastroenterol Hepatol 2008; 20: 465–8.

   OpenUrlPubMed
4. ↵
   Luke B, Hediger ML, Scholl TO. Point of diminishing returns: when does gestational weight gain cease benefiting birthweight and begin adding to maternal obesity? J Matern Fetal Med 1996; 5: 166–73.

   OpenUrl
5. ↵
   American Diabetes Association. Standards of medical care in diabetes—2008. Diabetes Care 2008; 31(Suppl 1): S12–S54.

   OpenUrlFREE Full Text
6. ↵
   American Diabetes Association. Living with diabetes. Diabetes PHD. Available at http://www.diabetes.org/living-with-diabetes/complications/diabetes-phd/. Accessed 15 March 2010.
7. ↵
   Eddy DM, Schlessinger L. Validation of the Archimedes diabetes model. Diabetes Care 2003; 26: 3102–10.

   OpenUrlAbstract/FREE Full Text
8. ↵
   Eddy DM, Schlessinger L. Archimedes: a trial-validated model of diabetes. Diabetes Care 2003; 26: 3093–101.

   OpenUrlAbstract/FREE Full Text
9. ↵
   Belch J, MacCuish A, Campbell I, et al. The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomized placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease. BMJ 2008; 337: a1840.

   OpenUrlAbstract/FREE Full Text
10. ↵
    Ogawa H, Nakayama M, Morimoto T, et al. Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes. JAMA 2008; 300: 2134–41.

    OpenUrlCrossRefPubMedWeb of Science
11. ↵
    US Preventive Services Task Force. Aspirin for the primary prevention of cardiovascular events. Report no. APPIP02-0004. Washington, DC: Agency for Healthcare Research and Quality.
12. ↵
    Kannel WB, Schatzkin A. Risk factor analysis. Prog Cardiovasc Dis 1983; 26: 309–32.

    OpenUrlWeb of Science
13. ↵
    Gerstein HC, Pogue J, Mann JFE, et al. The relationship between dysglycaemia and cardiovascular and renal risk in diabetic and non-diabetic participants in the HOPE study: a prospective epidemiological analysis. Diabetologia 2005; 48: 1749–55.

    OpenUrlCrossRefPubMedWeb of Science
14. Haffner SM. Is there a glycemic threshold?. Arch Intern Med 1997; 157: 1791.

    OpenUrlCrossRefPubMed
15. Krolewski AS, Laffel LMB, Krolewski BA, Quinn M, Warram JH. Glycosylated hemoglobin and the risk of microalbuminaria in patients with insulin-dependent diabetes mellitus. N Engl J Med 1995; 332: 1251–5.

    OpenUrlCrossRefPubMedWeb of Science
16. Orchard TJ, Forrest KY-Z, Ellis D, Becker D. Cumulative glycemic exposure and microvascular complications in insulin-dependent diabetes mellitus: the glycemic threshold revisited. Arch Intern Med 1997; 157: 1851–6.

    OpenUrlCrossRefPubMedWeb of Science
17. Vijan S, Hofer TP, Hayward RA. Estimated benefits of glycemic control in microvascular complications in type 2 diabetes. Ann Intern Med 1997; 127: 788–95.

    OpenUrlPubMedWeb of Science
18. Warram JH, Manson JE, Krolewski AS. Glycosylated hemoglobin and the risk of retinopathy in insulin-dependent diabetes mellitus. N Engl J Med 1995; 332: 1305–6.

    OpenUrlCrossRefPubMedWeb of Science
19. ↵
    Action to Control Cardiovascular Risk in Diabetes Study Group (ACCORD), Gerstein HC, Miller ME, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008; 358: 2545–59.

    OpenUrlCrossRefPubMedWeb of Science
20. ↵
    Courtney DL. Medication reduction strategies. Compr Ther 1996; 22: 318–23.

    OpenUrlPubMed
21. Stoehr GR, Lu S-Y, Lavery L, Vander Bilt J, Saxton JA, Chang C-C. Factors associated with adherence to medication regimens in older primary care patients: the Steel Valley Seniors Survey. Am J Geriatr Pharmacother 2008; 6: 255–63.

    OpenUrlCrossRefPubMed
22. ↵
    Williams AF, Manias E, Walker R. Adherence to multiple, prescribed medications in diabetic kidney disease: a qualitative study of consumers’ and health professionals’ perspectives. Int J Nurs Stud 2008; 45: 1742–56.

    OpenUrlCrossRefPubMedWeb of Science
23. ↵
    Boyd CM, Darer J, Boult C, Fried LP, Wu AW. Clinical practice guidelines and quality of care for older patients with multiple-co-morbid diseases: implications for pay for performance. JAMA 2005; 294: 716–24.

    OpenUrlCrossRefPubMedWeb of Science
24. ↵
    Mold JW. An alternative conceptualization of health and health care: its implications for geriatrics and gerontology. Educ Gerontol 1995; 21: 85–101.

    OpenUrlCrossRefWeb of Science
25. ↵
    Mold JW, Blake GH, Becker LA. Goal-oriented medical care. Fam Med 1991; 23: 46–51.

    OpenUrlPubMed
26. ↵
    Mold JW, Hamm R, Scheid D. Evidence-based medicine meets goal-directed health care. Fam Med 2003; 35: 360–4.

    OpenUrlPubMed
27. ↵
    Lee TH. “Me-Too” products—friend or foe? N Engl J Med 2004; 350: 211–2.

    OpenUrlCrossRefPubMedWeb of Science
28. ↵
    Zubialde JP, Mold JW. Relational value: bridging the worldview gap between patients and health systems. Fam Med 2001; 33: 393–8.

    OpenUrlPubMed
29. ↵
    Jacobson TA. “The lower the better” in hypercholesterolemia therapy: a reliable clinical guideline? Ann Intern Med 2000; 133: 549–54.

    OpenUrlPubMedWeb of Science
30. ↵
    Learmonth ID. Total hip replacement and the law of diminishing returns. J Bone Joint Surg 2006; 88-A: 1664–73.

    OpenUrlCrossRefPubMed